<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01175538</url>
  </required_header>
  <id_info>
    <org_study_id>PS001</org_study_id>
    <nct_id>NCT01175538</nct_id>
  </id_info>
  <brief_title>Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis</brief_title>
  <official_title>Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Govind Ballabh Pant Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Govind Ballabh Pant Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effects of lactulose for the prevention of first episode of altered sensorium
      (hepatic encephalopathy, primary prophylaxis) in patients with cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Development of hepatic encephalopathy in a patient with cirrhosis is associated with poor
      survival rate of 10-70% at one year depending upon hepatic and renal functions. Treating
      patients to prevent development of first episode of hepatic encephalopathy is classified as
      primary prophylaxis of hepatic encephalopathy and preventing recurrence of hepatic
      encephalopathy in patients who had previous episode of hepatic encephalopathy is secondary
      prophylaxis of hepatic encephalopathy
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">September 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>prevention of first episode of hepatic encephalopathy</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects to lactulose and mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Lactulose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose</intervention_name>
    <description>In the Gp-L group, patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day</description>
    <arm_group_label>Lactulose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose</intervention_name>
    <description>lactulose will be used in 30-60ml/day</description>
    <arm_group_label>Lactulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cirrhotic patients(18-70yrs) who never had encephalopathy

        Exclusion Criteria:

          -  history of taking lactulose in the past 6 weeks

          -  alcohol intake during the past 6 weeks

          -  hepatocellular carcinoma

          -  previous TIPS or shunt surgery

          -  significant co morbid illness such as heart, respiratory, or renal failure

          -  neurologic diseases such as alzheimer's disease, parkinson's disease and nonhepatic
             metabolic encephalopathies.

          -  patients on psychoactive drugs such as antidepressants or sedatives

          -  who restarted alcohol during follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barjesh C Sharma, MD,DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>G B Pant Hospital New Delhi 110002</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barjesh C Sharma, MD,DM</last_name>
    <phone>9718599203</phone>
    <email>drbcsharma@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>G B Pant Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barjesh C Sharma, MD,DM</last_name>
      <phone>9718599203</phone>
      <email>drbcsharma@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Praveen Sharma, MD,DM</last_name>
      <phone>9810365151</phone>
      <email>drpraveen_sharma@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Barjesh C Sharma, MD,DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2010</study_first_submitted>
  <study_first_submitted_qc>August 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2010</study_first_posted>
  <last_update_submitted>August 4, 2010</last_update_submitted>
  <last_update_submitted_qc>August 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof Barjesh Chander Sharma</name_title>
    <organization>G B Pant Hospital</organization>
  </responsible_party>
  <keyword>Hepatic encephalopathy</keyword>
  <keyword>Lactulose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

